@article{MTMT:34801056,
	title = {The perioperative period of heart transplantation is affected by thyroid hormone status},
	url = {https://m2.mtmt.hu/api/publication/34801056},
	author = {Szécsi, Balázs and Sinkó, Richárd and Vereb, Alexandra and Khochanskiy, Dmitry and Benke, Kálmán and Radovits, Tamás and Lakatos, Bálint and Kőszegi, Andrea and Losoncz, Eszter and Kugler, Szilvia and Szabó, Márk and Merkely, Béla Péter and Székely, Andrea and Gereben, Balázs},
	doi = {10.1089/thy.2023.0628},
	journal-iso = {THYROID},
	journal = {THYROID},
	unique-id = {34801056},
	issn = {1050-7256},
	year = {2024},
	eissn = {1557-9077},
	orcid-numbers = {Szécsi, Balázs/0000-0003-2341-7389; Vereb, Alexandra/0009-0007-1488-3595; Benke, Kálmán/0000-0001-7885-2543; Lakatos, Bálint/0000-0002-7627-5620; Losoncz, Eszter/0000-0001-6426-8821; Merkely, Béla Péter/0000-0001-6514-0723; Székely, Andrea/0000-0002-1382-7897}
}

@article{MTMT:34747533,
	title = {Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists :$bThe "THESIS"* collaboration (*Treatment of Hypothyroidism in Europe by Specialists, an International Survey)},
	url = {https://m2.mtmt.hu/api/publication/34747533},
	author = {Roberto, Attanasio and Miloš, Žarković and Enrico, Papini and Nagy, Endre and Roberto, Negro and Petros, Perros and Ersin, Akarsu and Maria, Alevizaki and Göksun, Ayvaz and Tomasz, Bednarczuk and Biljana, Beleslin and Berta, Eszter and Bodor, Miklós and Anna, Maria Borissova and Mihail, Boyanov and Camille, Buffet and Maria-Cristina, Burlacu and Jasmina, Ciric and Juan, J. Díez and Harald, Dobnig and Valentin, V. Fadeyev and Benjamin, C. T. Field and Eric, Fliers and Dagmar, Führer and Juan, Carlos Galofré and Tommi, Hakala and Jan, Jiskra and Peter, A. Kopp and Michael, Krebs and Michal, Kršek and Martin, Kuzma and Mikael, Lantz and Ivica, Lazúrová and Laurence, Leenhardt and Vitaliy, Luchytskiy and Francisca, Marques Puga and Anne, McGowan and Saara, Metso and Carla, Moran and Tatyana, Morgunova and Dan, Alexandru Niculescu and Božidar, Perić and Tereza, Planck and Catalina, Poiana and Eyal, Robenshtok and Patrick, Olivier Rosselet and Marek, Ruchala and Kamilla, Ryom Riis and Alla, Shepelkevich and Mykola, D. Tronko and David, Unuane and Irfan, Vardarli and W., Edward Visser and Andromachi, Vryonidou and Younes, Ramazan Younes and Laszlo, Hegedus},
	journal-iso = {THYROID},
	journal = {THYROID},
	unique-id = {34747533},
	issn = {1050-7256},
	year = {2024},
	eissn = {1557-9077}
}

@article{MTMT:34680786,
	title = {Clinical Outcomes of Thermal Ablation Re-Treatment of Benign Thyroid Nodules: A Multicenter Study from the Italian Minimally Invasive Treatments of the Thyroid Group},
	url = {https://m2.mtmt.hu/api/publication/34680786},
	author = {Bernardi, Stella and Rosolen, Valentina and Barbone, Fabio and Borgato, Stefano and Deandrea, Maurilio and De Feo, Pierpaolo and Fugazzola, Laura and Gambelunghe, Giovanni and Negro, Roberto and Oleandri, Salvatore and Papi, Giampaolo and Papini, Enrico and Retta, Francesca and Rossetto, Ruth and Sansone, Daniela and Serra, Giuseppe and Sconfienza, Luca Maria and Solbiati, Luigi and Spiezia, Stefano and Stacul, Fulvio and Mauri, Giovanni},
	doi = {10.1089/thy.2023.0501},
	journal-iso = {THYROID},
	journal = {THYROID},
	unique-id = {34680786},
	issn = {1050-7256},
	keywords = {LASER; radiofrequency ablation; thyroid nodules; Thermal ablation; Re-treatment; second treatment},
	year = {2024},
	eissn = {1557-9077},
	orcid-numbers = {Bernardi, Stella/0000-0002-7429-3075; Serra, Giuseppe/0009-0007-5358-7369}
}

@article{MTMT:34646748,
	title = {Maternal Thyroid Dysfunction During Pregnancy as an Etiologic Factor in Autism Spectrum Disorder: Challenges and Opportunities for Research},
	url = {https://m2.mtmt.hu/api/publication/34646748},
	author = {Kaplan, Zoe B. and Pearce, Elizabeth N. and Lee, Sun Y. and Shin, Hyeong-Moo and Schmidt, Rebecca J.},
	doi = {10.1089/thy.2023.0391},
	journal-iso = {THYROID},
	journal = {THYROID},
	unique-id = {34646748},
	issn = {1050-7256},
	keywords = {prenatal exposure; hyperthyroidism; HYPOTHYROIDISM; Autism Spectrum Disorder; thyroid dysfunction; Delayed effects},
	year = {2024},
	eissn = {1557-9077}
}

@article{MTMT:34598486,
	title = {Optimizing Diagnostic Accuracy of Fine Needle Aspiration Biopsy Calcitonin Measurements in Detecting Medullary Thyroid Carcinoma},
	url = {https://m2.mtmt.hu/api/publication/34598486},
	author = {Cavallo, Andrea Camila and Pitoia, Fabian and Roberti, Javier and Brenzoni, Pablo and Lencioni, Melisa and Jaroslavsky, Maria Jose and Spengler, Eunice and Voogd, Ana and Firpo, Claudia and Saco, Pedro and Pinero, Federico and Negueruela, Maria},
	doi = {10.1089/thy.2023.0313},
	journal-iso = {THYROID},
	journal = {THYROID},
	unique-id = {34598486},
	issn = {1050-7256},
	abstract = {Background: The optimal cutoff value of calcitonin (Ctn) levels measured using an electrochemiluminescence immunoassay (ECLIA) obtained from the washout fluid of fine needle aspiration (FNA-Ctn) for the diagnosis of medullary thyroid carcinoma (MTC) is currently not established. We evaluated the diagnostic accuracy and clinical utility of FNA-Ctn for the diagnosis and location of MTC in patients with nodular or multinodular goiters. Methods: This was a case-control study nested on a prospective multicenter cohort of patients with nodular or multinodular goiter, normal or elevated serum Ctn, and thyroidectomy indications. Ctn and FNA-Ctn were measured using ECLIA methodology before surgery. From this nested cohort, MTC cases and controls (non-medullary pathology) were identified from the final pathological analysis. Cumulative incidence sampling of controls was randomly performed at a ratio of 1:2. Sensitivity, specificity, and area under the receiver operator curve (AUROC) were calculated for patients and the total number of thyroid nodules. Results: From 1272 patients included in the prospective cohort, 50 MTC cases and 105 controls were included. In this study, 286 thyroid nodules were evaluated (63 MTC and 223 non-MTCs). The median serum Ctn value was significantly higher in cases (525 pg/mL [interquartile range (IQR), 162.5-1.200]) than in controls (1.6 pg/mL [IQR, 0.5-5.6]; p < 0.001). The median FNA-Ctn value was significantly higher in MTC nodules (3.100 pg/mL [IQR, 450-45,200]) than in non-MTC nodules (0.5 pg/mL [IQR, 0.5-0.5]; p < 0.0001). In 11 MTC patients with multinodular goiter, the FNA-Ctn value was significantly higher in non-medullary nodules located in the same lobe where an MTC nodule was diagnosed (p = 0.0002). Overall, the FNA-Ctn AUROC was 0.99 [95% confidence interval, 0.98-1.0], and a threshold of >= 220 pg/mL showed 100% sensitivity and 98% specificity for MTC diagnosis. Conclusions: The use of FNA-Ctn measured by ECLIA showed adequate diagnostic accuracy for MTC diagnosis. Moreover, it may be clinically useful for localization in multinodular goiter when lobectomy is considered.},
	keywords = {CALCITONIN; Medullary thyroid carcinoma; calcitonin in washout fluid of fine needle aspiration},
	year = {2024},
	eissn = {1557-9077},
	orcid-numbers = {Pitoia, Fabian/0000-0002-2742-7085}
}

@article{MTMT:34578010,
	title = {Regulation of Thyroid Hormone Gatekeepers by Thyrotropin in Tanycytes},
	url = {https://m2.mtmt.hu/api/publication/34578010},
	author = {Chandrasekar, Akila and Schmidtlein, Paula Marie and Neve, Vanessa and Rivagorda, Manon and Spiecker, Frauke and Gauthier, Karine and Prevot, Vincent and Schwaninger, Markus and Mueller-Fielitz, Helge},
	doi = {10.1089/thy.2023.0375},
	journal-iso = {THYROID},
	journal = {THYROID},
	unique-id = {34578010},
	issn = {1050-7256},
	abstract = {Background: Tanycytes are specialized glial cells within the mediobasal hypothalamus that have multiple functions, including hormone sensing and regulation of hypophysiotropic hormone secretion. There are ongoing discussions about the role of tanycytes in regulating the supply of hypothalamic thyroid hormones (THs) through the expression of TH transporters (Slc16a2, Slco1c1) and deiodinases (Dio2, Dio3). In this study, we investigated the potential feedback effect of thyrotropin (TSH) on the transcription of these gatekeeper genes on tanycytes.Methods: We analyzed the changes in the expression of TH-gatekeeper genes, in TSH-stimulated primary tanycytes, using quantitative polymerase chain reaction (qPCR). We also used RNAScope (R) in brain slices to further reveal the local distribution of the transcripts. In addition, we blocked intracellular pathways and used small-interfering RNA (siRNA) to elucidate differences in the regulation of the gatekeeper genes.Results: TSH elevated messenger RNA (mRNA) levels of Slco1c1, Dio2, and Dio3 in tanycytes, while Slc16a2 was mostly unaffected. Blockade and knockdown of the TSH receptor (TSHR) and antagonization of cAMP response element-binding protein (CREB) clearly abolished the increased expression induced by TSH, indicating PKA-dependent regulation through the TSHR. The TSH-dependent expression of Dio3 and Slco1c1 was also regulated by protein kinase C (PKC), and in case of Dio3, also by extracellular signal-regulated kinase (ERK) activity. Importantly, these gene regulations were specifically found in different subpopulations of tanycytes.Conclusions: This study demonstrates that TSH induces transcriptional regulation of TH-gatekeeper genes in tanycytes through the Tshr/G alpha q/PKC pathway, in parallel to the Tshr/G alpha s/PKA/CREB pathway. These differential actions of TSH on tanycytic subpopulations appear to be important for coordinating the supply of TH to the hypothalamus and aid its functions.},
	keywords = {PKC; pKa; tanycytes; TSH; Deiodinase; Thyroid hormone transporter},
	year = {2024},
	eissn = {1557-9077}
}

@article{MTMT:34558160,
	title = {Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology. A Subgroup Analysis of the COSMIC-311 Study.},
	url = {https://m2.mtmt.hu/api/publication/34558160},
	author = {Capdevila, Jaume and Krajewska, Jolanta and Hernando, Jorge and Robinson, Bruce and Sherman, Steven I and Jarzab, Barbara and Lin, Chia-Chi and Vaisman, Fernanda and Hoff, Ana O and Hitre, Erika and Bowles, Daniel W and Williamson, Denise and Levytskyy, Roman and Oliver, Jennifer and Keam, Bhumsuk and Brose, Marcia S},
	doi = {10.1089/thy.2023.0463},
	journal-iso = {THYROID},
	journal = {THYROID},
	volume = {34},
	unique-id = {34558160},
	issn = {1050-7256},
	abstract = {Background: Lenvatinib and sorafenib are standard of care first-line treatments for advanced, radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC). However, most patients eventually become treatment-resistant and require additional therapies. The phase 3 COSMIC-311 study investigated cabozantinib in patients with RAIR DTC who progressed on lenvatinib, sorafenib, or both and showed that cabozantinib provided substantial clinical benefit. Presented in this study is an analysis of COSMIC-311 based on prior therapy and histology. Methods: Patients were randomized 2:1 (stratification: prior lenvatinib [yes/no]; age [≤65, >65 years]) to oral cabozantinib (60 mg tablet/day) or matched placebo. Eligible patients received 1-2 prior vascular endothelial growth factor receptor-targeting tyrosine kinase inhibitors for DTC (lenvatinib or sorafenib required), had a confirmed DTC diagnosis, and were refractory to or ineligible for radioiodine therapy. For this analysis, progression-free survival (PFS) and objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 by a blinded independent radiology committee were evaluated by prior therapy (lenvatinib only, sorafenib only, both) and histology (papillary, follicular, oncocytic, poorly differentiated). Results: Two hundred fifty-eight patients were randomized (170 cabozantinib/88 placebo) who previously received sorafenib only (n = 96), lenvatinib only (n = 102), or both (n = 60). The median follow-up was 10.1 months. The median PFS (months) with cabozantinib/placebo was 16.6/3.2 (sorafenib only: hazard ratio [HR] 0.13 [95% confidence interval, CI, 0.06-0.26]), 5.8/1.9 (lenvatinib only: HR 0.28 [95% CI 0.16-0.48]), and 7.6/1.9 (both: HR 0.27 [95% CI 0.13-0.54]). The ORR with cabozantinib/placebo was 21%/0% (sorafenib only), 4%/0% (lenvatinib only), and 8%/0% (both). Disease histology consisted of 150 papillary and 113 follicular, including 43 oncocytic and 36 poorly differentiated. The median PFS (months) with cabozantinib/placebo was 9.2/1.9 (papillary: HR 0.27 [95% CI 0.17-0.43]), 11.2/2.5 (follicular: HR 0.18 [95% CI 0.10-0.31]), 11.2/2.5 (oncocytic: HR 0.06 [95% CI 0.02-0.21]), and 7.4/1.8 (poorly differentiated: HR 0.18 [95% CI 0.08-0.43]). The ORR with cabozantinib/placebo was 15%/0% (papillary), 8%/0% (follicular), 11%/0% (oncocytic), and 9%/0% (poorly differentiated). Safety outcomes evaluated were consistent with those previously observed for the overall population. Conclusions: Results indicate that cabozantinib benefits patients with RAIR DTC, regardless of prior lenvatinib or sorafenib treatments or histology. Clinical Trial Registration Number: NCT03690388.},
	keywords = {PAPILLARY; Lenvatinib; cabozantinib; Follicular; radioiodine-refractory differentiated thyroid cancer; COSMIC-311},
	year = {2024},
	eissn = {1557-9077},
	pages = {347-359}
}

@article{MTMT:34751104,
	title = {Weighing in on Thyroid Signaling in the Hypothalamus: Mechanisms and Interface with Metabolic Regulators},
	url = {https://m2.mtmt.hu/api/publication/34751104},
	author = {Milanesi, A. and Brent, G.A.},
	doi = {10.1089/thy.2024.0031},
	journal-iso = {THYROID},
	journal = {THYROID},
	volume = {34},
	unique-id = {34751104},
	issn = {1050-7256},
	keywords = {Humans; metabolism; ARCUATE NUCLEUS; THERMOREGULATION; signal transduction; signal transduction; signal transduction; human; Brain Mapping; Gene Expression; note; liothyronine; messenger rna; thyroid gland; thyroid gland; food intake; HYPOTHYROIDISM; body temperature; neuropeptide Y; metabolic regulation; thyroxine; cyclic AMP responsive element binding protein; PARAVENTRICULAR THALAMIC NUCLEUS; Appetite; Thyrotropin; thyroid function test; glia cell; feedback system; Thyroid hormone; hormone response; median eminence; soleus muscle; protirelin; intracellular signaling; cell nucleus receptor; 3,3',5' triiodothyronine; thyrotropin receptor; brown adipose tissue; thyroid hormone receptor; glucagon like peptide 1; brain third ventricle; thyroid hormone receptor beta; hypothalamus hypophysis thyroid system; thyroxine deiodinase; tanycyte; hypothalamus hormone; glucagon like peptide 1 receptor; hypothalamus; hypothalamus},
	year = {2024},
	eissn = {1557-9077},
	pages = {141-143}
}

@article{MTMT:34578220,
	title = {GLP-1 Receptor Signaling Has Different Effects on the Perikarya and Axons of the Hypophysiotropic Thyrotropin-Releasing Hormone Synthesizing Neurons in Male Mice},
	url = {https://m2.mtmt.hu/api/publication/34578220},
	author = {Ruska, Yvette Magdolna and Péterfi, Zoltán Attila and Stiftné Szilvásy-Szabó, Anett and Kővári, Dóra and Hrabovszky, Erik and Dorogházi, Beáta Vanessza and Gereben, Balázs and Tóth, Blanka and Matziari, Magdalini and Wittmann, Gábor and Fekete, Csaba},
	doi = {10.1089/thy.2023.0284},
	journal-iso = {THYROID},
	journal = {THYROID},
	volume = {34},
	unique-id = {34578220},
	issn = {1050-7256},
	abstract = {Background: Glucagon-like peptide 1 (GLP-1) is involved in the regulation of energy and glucose homeostasis. As GLP-1 has similar effects on the energy homeostasis as the hypophysiotropic thyrotropin-releasing hormone (TRH) neurons that regulate the hypothalamic-pituitary-thyroid (HPT) axis, we raised the possibility that the TRH neurons are involved in the mediation of the effects of GLP-1. Therefore, the relationship and interaction of the GLP-1 system and the TRH neurons of the hypothalamic paraventricular nucleus (PVN) were studied.Methods: To examine the anatomical and functional relationship of TRH neurons and the GLP-1 system in the PVN, immunocytochemistry, in situ hybridization, in vitro patch-clamp electrophysiology, metabolic phenotyping, and explant experiments were performed.Results: Our data demonstrate that the TRH neurons of the PVN are innervated by GLP-1 producing neurons and express the GLP-1 receptor (GLP-1R). However, not only do the GLP-1-innervated TRH neurons express GLP-1R but the receptor is also present in the axons of the hypophysiotropic TRH neurons in the blood-brain barrier free median eminence (ME) suggesting that peripherally derived GLP-1 may also influence the TRH neurons. In vitro, GLP-1 increased the firing rate of TRH neurons and depolarized them. In addition, GLP-1 directly stimulated the GABAergic input of a population of TRH neurons. Furthermore, GLP-1 inhibited the release of TRH from the hypophysiotropic axons in the ME. In vivo, peripheral GLP-1R agonist administration markedly inhibited the food intake and the energy expenditure, but had no effect on the TRH expression in the PVN and resulted in lower circulating free T4 levels.Conclusions: Our results indicate that GLP-1R activation has a direct stimulatory effect on TRH neurons in the PVN, but the activation of GLP-1R may also inhibit TRH neurons by facilitating their inhibitory inputs or by inhibiting the axon terminals of these cells in the ME. The innervation of TRH neurons by GLP-1 neurons suggests that TRH neurons might be influenced by both circulating GLP-1 and by GLP-1 neurons of the nucleus tractus solitarii. The lack of GLP-1R agonist-induced regulation of TRH neurons in vivo suggests that the HPT axis does not mediate the GLP-1R agonist-induced weight loss.},
	keywords = {Release; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; median eminence; TRH; Glucagon-like peptide-1 receptor},
	year = {2024},
	eissn = {1557-9077},
	pages = {252-260},
	orcid-numbers = {Kővári, Dóra/0000-0001-5346-822X}
}

@article{MTMT:34672491,
	title = {Clinical and Surgical Year in Review},
	url = {https://m2.mtmt.hu/api/publication/34672491},
	author = {Goldner, Whitney and Sinclair, Catherine},
	doi = {10.1089/thy.2023.0601},
	journal-iso = {THYROID},
	journal = {THYROID},
	volume = {34},
	unique-id = {34672491},
	issn = {1050-7256},
	year = {2024},
	eissn = {1557-9077},
	pages = {3-9}
}